Oncology Diagnostics Attracts Big Money
MORE SURPRISING DEVELOPMENTS for the anatomic pathology profession during the past three weeks! The impending $215 million acquisition ofĀ IMPATH, Inc. by Genzyme Corporation, announced on March 1, has the potential to send new ripples across the national market for oncology testing. What makes the GenzymeāIMPATH combination particularly fascinating was the $1 billion Genzyme paid, just …